Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa
Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in LAMA3, LAMB3, or LAMC2, leading to complete loss of laminin 332, the major component of anc...
Saved in:
| Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 115; no. 28; pp. E6536 - E6545 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
National Academy of Sciences
10.07.2018
|
| Series | PNAS Plus |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0027-8424 1091-6490 1091-6490 |
| DOI | 10.1073/pnas.1803154115 |
Cover
| Abstract | Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in LAMA3, LAMB3, or LAMC2, leading to complete loss of laminin 332, the major component of anchoring filaments, which mediate epidermal-dermal adherence. LAMB3 (laminin β3) mutations account for 80% of patients with H-JEB, and ∼95% of H-JEB–associated LAMB3 mutations are nonsense mutations leading to premature termination codons (PTCs). In this study, we evaluated the ability of gentamicin to induce PTC readthrough in H-JEB laminin β3-null keratinocytes transfected with expression vectors encoding eight different LAMB3 nonsense mutations. We found that gentamicin induced PTC readthrough in all eight nonsense mutations tested. We next used lentiviral vectors to generate stably transduced H-JEB cells with the R635X and C290X nonsense mutations. Incubation of these cell lines with various concentrations of gentamicin resulted in the synthesis and secretion of full-length laminin β3 in a dose-dependent and sustained manner. Importantly, the gentamicin-induced laminin β3 led to the restoration of laminin 332 assembly, secretion, and deposition within the dermal/epidermal junction, as well as proper polarization of α6β4 integrin in basal keratinocytes, as assessed by immunoblot analysis, immunofluorescent microscopy, and an in vitro 3D skin equivalent model. Finally, newly restored laminin 332 corrected the abnormal cellular phenotype of H-JEB cells by reversing abnormal cell morphology, poor growth potential, poor cell-substratum adhesion, and hypermotility. Therefore, gentamicin may offer a therapy for H-JEB and other inherited skin diseases caused by PTC mutations. |
|---|---|
| AbstractList | Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in LAMA3, LAMB3, or LAMC2, leading to complete loss of laminin 332, the major component of anchoring filaments, which mediate epidermal-dermal adherence. LAMB3 (laminin β3) mutations account for 80% of patients with H-JEB, and ∼95% of H-JEB–associated LAMB3 mutations are nonsense mutations leading to premature termination codons (PTCs). In this study, we evaluated the ability of gentamicin to induce PTC readthrough in H-JEB laminin β3-null keratinocytes transfected with expression vectors encoding eight different LAMB3 nonsense mutations. We found that gentamicin induced PTC readthrough in all eight nonsense mutations tested. We next used lentiviral vectors to generate stably transduced H-JEB cells with the R635X and C290X nonsense mutations. Incubation of these cell lines with various concentrations of gentamicin resulted in the synthesis and secretion of full-length laminin β3 in a dose-dependent and sustained manner. Importantly, the gentamicin-induced laminin β3 led to the restoration of laminin 332 assembly, secretion, and deposition within the dermal/epidermal junction, as well as proper polarization of α6β4 integrin in basal keratinocytes, as assessed by immunoblot analysis, immunofluorescent microscopy, and an in vitro 3D skin equivalent model. Finally, newly restored laminin 332 corrected the abnormal cellular phenotype of H-JEB cells by reversing abnormal cell morphology, poor growth potential, poor cell-substratum adhesion, and hypermotility. Therefore, gentamicin may offer a therapy for H-JEB and other inherited skin diseases caused by PTC mutations. Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in , , or , leading to complete loss of laminin 332, the major component of anchoring filaments, which mediate epidermal-dermal adherence. (laminin β3) mutations account for 80% of patients with H-JEB, and ∼95% of H-JEB-associated mutations are nonsense mutations leading to premature termination codons (PTCs). In this study, we evaluated the ability of gentamicin to induce PTC readthrough in H-JEB laminin β3-null keratinocytes transfected with expression vectors encoding eight different nonsense mutations. We found that gentamicin induced PTC readthrough in all eight nonsense mutations tested. We next used lentiviral vectors to generate stably transduced H-JEB cells with the R635X and C290X nonsense mutations. Incubation of these cell lines with various concentrations of gentamicin resulted in the synthesis and secretion of full-length laminin β3 in a dose-dependent and sustained manner. Importantly, the gentamicin-induced laminin β3 led to the restoration of laminin 332 assembly, secretion, and deposition within the dermal/epidermal junction, as well as proper polarization of α6β4 integrin in basal keratinocytes, as assessed by immunoblot analysis, immunofluorescent microscopy, and an in vitro 3D skin equivalent model. Finally, newly restored laminin 332 corrected the abnormal cellular phenotype of H-JEB cells by reversing abnormal cell morphology, poor growth potential, poor cell-substratum adhesion, and hypermotility. Therefore, gentamicin may offer a therapy for H-JEB and other inherited skin diseases caused by PTC mutations. Premature termination codons (PTCs) generated by nonsense mutations produce abnormal, short, or diminished proteins. Eighty-three percent of patients with Herlitz junctional epidermolysis bullosa (H-JEB), an inherited, incurable skin disease, harbor nonsense mutation(s) in genes encoding a structural protein (laminin 332) responsible for skin adherence. Gentamicin, a common antibiotic, was shown to induce readthrough of PTCs in various disease models. Using in vitro assays and 3D skin models, we found that H-JEB cells harboring nonsense mutations exposed to gentamicin produce full-length structural protein, deposit it correctly between skin layers, and exhibit reversal of other H-JEB–associated cellular abnormalities. Our findings indicate that gentamicin may present an immediate therapy for this otherwise fatal disease and other skin disorders caused by nonsense mutations. Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in LAMA3 , LAMB3 , or LAMC2 , leading to complete loss of laminin 332, the major component of anchoring filaments, which mediate epidermal-dermal adherence. LAMB3 (laminin β3) mutations account for 80% of patients with H-JEB, and ∼95% of H-JEB–associated LAMB3 mutations are nonsense mutations leading to premature termination codons (PTCs). In this study, we evaluated the ability of gentamicin to induce PTC readthrough in H-JEB laminin β3-null keratinocytes transfected with expression vectors encoding eight different LAMB3 nonsense mutations. We found that gentamicin induced PTC readthrough in all eight nonsense mutations tested. We next used lentiviral vectors to generate stably transduced H-JEB cells with the R635X and C290X nonsense mutations. Incubation of these cell lines with various concentrations of gentamicin resulted in the synthesis and secretion of full-length laminin β3 in a dose-dependent and sustained manner. Importantly, the gentamicin-induced laminin β3 led to the restoration of laminin 332 assembly, secretion, and deposition within the dermal/epidermal junction, as well as proper polarization of α6β4 integrin in basal keratinocytes, as assessed by immunoblot analysis, immunofluorescent microscopy, and an in vitro 3D skin equivalent model. Finally, newly restored laminin 332 corrected the abnormal cellular phenotype of H-JEB cells by reversing abnormal cell morphology, poor growth potential, poor cell-substratum adhesion, and hypermotility. Therefore, gentamicin may offer a therapy for H-JEB and other inherited skin diseases caused by PTC mutations. Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in LAMA3, LAMB3, or LAMC2, leading to complete loss of laminin 332, the major component of anchoring filaments, which mediate epidermal-dermal adherence. LAMB3 (laminin β3) mutations account for 80% of patients with H-JEB, and ∼95% of H-JEB-associated LAMB3 mutations are nonsense mutations leading to premature termination codons (PTCs). In this study, we evaluated the ability of gentamicin to induce PTC readthrough in H-JEB laminin β3-null keratinocytes transfected with expression vectors encoding eight different LAMB3 nonsense mutations. We found that gentamicin induced PTC readthrough in all eight nonsense mutations tested. We next used lentiviral vectors to generate stably transduced H-JEB cells with the R635X and C290X nonsense mutations. Incubation of these cell lines with various concentrations of gentamicin resulted in the synthesis and secretion of full-length laminin β3 in a dose-dependent and sustained manner. Importantly, the gentamicin-induced laminin β3 led to the restoration of laminin 332 assembly, secretion, and deposition within the dermal/epidermal junction, as well as proper polarization of α6β4 integrin in basal keratinocytes, as assessed by immunoblot analysis, immunofluorescent microscopy, and an in vitro 3D skin equivalent model. Finally, newly restored laminin 332 corrected the abnormal cellular phenotype of H-JEB cells by reversing abnormal cell morphology, poor growth potential, poor cell-substratum adhesion, and hypermotility. Therefore, gentamicin may offer a therapy for H-JEB and other inherited skin diseases caused by PTC mutations.Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care. H-JEB is caused by loss-of-function mutations in LAMA3, LAMB3, or LAMC2, leading to complete loss of laminin 332, the major component of anchoring filaments, which mediate epidermal-dermal adherence. LAMB3 (laminin β3) mutations account for 80% of patients with H-JEB, and ∼95% of H-JEB-associated LAMB3 mutations are nonsense mutations leading to premature termination codons (PTCs). In this study, we evaluated the ability of gentamicin to induce PTC readthrough in H-JEB laminin β3-null keratinocytes transfected with expression vectors encoding eight different LAMB3 nonsense mutations. We found that gentamicin induced PTC readthrough in all eight nonsense mutations tested. We next used lentiviral vectors to generate stably transduced H-JEB cells with the R635X and C290X nonsense mutations. Incubation of these cell lines with various concentrations of gentamicin resulted in the synthesis and secretion of full-length laminin β3 in a dose-dependent and sustained manner. Importantly, the gentamicin-induced laminin β3 led to the restoration of laminin 332 assembly, secretion, and deposition within the dermal/epidermal junction, as well as proper polarization of α6β4 integrin in basal keratinocytes, as assessed by immunoblot analysis, immunofluorescent microscopy, and an in vitro 3D skin equivalent model. Finally, newly restored laminin 332 corrected the abnormal cellular phenotype of H-JEB cells by reversing abnormal cell morphology, poor growth potential, poor cell-substratum adhesion, and hypermotility. Therefore, gentamicin may offer a therapy for H-JEB and other inherited skin diseases caused by PTC mutations. |
| Author | Lincoln, Vadim Hou, Yingping De Rosa, Laura Cogan, Jon Chen, Mei Hirsch, Michaela Hao, Michelle Bauer, Johann W. Woodley, David T. Alexeev, Vitali De Luca, Michele |
| Author_xml | – sequence: 1 givenname: Vadim surname: Lincoln fullname: Lincoln, Vadim organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 – sequence: 2 givenname: Jon surname: Cogan fullname: Cogan, Jon organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 – sequence: 3 givenname: Yingping surname: Hou fullname: Hou, Yingping organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 – sequence: 4 givenname: Michaela surname: Hirsch fullname: Hirsch, Michaela organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 – sequence: 5 givenname: Michelle surname: Hao fullname: Hao, Michelle organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 – sequence: 6 givenname: Vitali surname: Alexeev fullname: Alexeev, Vitali organization: Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 19107 – sequence: 7 givenname: Michele surname: De Luca fullname: De Luca, Michele organization: Center for Regenerative Medicine “Stefano Ferrari,” Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy – sequence: 8 givenname: Laura surname: De Rosa fullname: De Rosa, Laura organization: Center for Regenerative Medicine “Stefano Ferrari,” Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy – sequence: 9 givenname: Johann W. surname: Bauer fullname: Bauer, Johann W. organization: EB House Austria and Department of Dermatology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria – sequence: 10 givenname: David T. surname: Woodley fullname: Woodley, David T. organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 – sequence: 11 givenname: Mei surname: Chen fullname: Chen, Mei organization: Department of Dermatology, The Keck School of Medicine of University of Southern California, Los Angeles, CA 90033 |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29946029$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kkFv1DAQhS1URLeFMyeQJS5c0o5jJ2tfkEoFBWkRFzhbjjPpeuXYi50g9cJvx9GWLvSAFDmy5nvPM34-IychBiTkJYMLBmt-uQ8mXzAJnDWCseYJWTFQrGqFghOyAqjXlRS1OCVnOe8AQDUSnpHTWinRQq1W5NcNhsmMzrpAXehni5lurr6857SclLF8dJwnM7kYaELTT9sU59stNaEv-zzFstBhDnYhjKe-eIXixXld_OjuWMG96zGN0d9ll2k3ex-zeU6eDsZnfHH_PyffP374dv2p2ny9-Xx9tamsgHqqlGTYrVkLyKQwaNuuZ4oxRFSGc9WxZpCN7CS3fd8udYVWiR5B1AOqwfJz8u7gu5-7EXtbhk7G631yo0l3Ohqn_60Et9W38aduQUih1sXg7b1Bij_mMrgeXbbovQkY56xraEG2CqQs6JtH6C7OqVxBoRgUAhrghXr9d0cPrfyJpgCXB8CmmHPC4QFhoJfw9RK-PoZfFM0jhXWH6MpIzv9H9-qg2y15Hjtpm_KYeMN_AxBwwNI |
| CitedBy_id | crossref_primary_10_1016_j_biopha_2024_117233 crossref_primary_10_1016_j_omtn_2024_102334 crossref_primary_10_1101_cshperspect_a041229 crossref_primary_10_1016_j_ymthe_2020_03_006 crossref_primary_10_1016_j_xjidi_2023_100240 crossref_primary_10_1111_exd_14484 crossref_primary_10_1016_j_jid_2023_08_021 crossref_primary_10_1242_dmm_043281 crossref_primary_10_2147_IJGM_S342740 crossref_primary_10_1111_bjd_18870 crossref_primary_10_1080_14712598_2020_1740678 crossref_primary_10_1038_s42003_023_05747_5 crossref_primary_10_1001_jamadermatol_2021_5992 crossref_primary_10_1093_hmg_ddz280 crossref_primary_10_1002_jvc2_343 crossref_primary_10_1111_bjd_18921 crossref_primary_10_3390_pharmaceutics14020319 crossref_primary_10_1007_s00018_021_03809_7 crossref_primary_10_1007_s40257_021_00626_3 crossref_primary_10_1016_j_isci_2022_103891 crossref_primary_10_1007_s40291_020_00466_7 crossref_primary_10_1111_exd_14194 crossref_primary_10_1001_jamadermatol_2022_0112 crossref_primary_10_1080_14728214_2020_1839049 crossref_primary_10_3389_fphar_2021_746664 crossref_primary_10_1111_exd_15042 crossref_primary_10_1615_CritRevImmunol_2023051066 crossref_primary_10_3892_ol_2019_10600 crossref_primary_10_1016_j_jdermsci_2021_11_004 crossref_primary_10_1080_10409238_2021_1901255 crossref_primary_10_1111_ceo_13912 crossref_primary_10_1016_j_jid_2021_09_018 crossref_primary_10_1007_s12326_024_00627_z crossref_primary_10_4103_idoj_idoj_554_21 crossref_primary_10_25208_vdv1107 crossref_primary_10_1016_j_semcdb_2021_03_025 crossref_primary_10_1016_j_ddmod_2020_10_001 crossref_primary_10_1016_j_omtn_2023_06_018 crossref_primary_10_1111_exd_13979 crossref_primary_10_3389_fmed_2018_00363 crossref_primary_10_1016_j_jid_2024_04_032 crossref_primary_10_25208_vdv16737 crossref_primary_10_1007_s12519_021_00469_2 crossref_primary_10_1016_j_jid_2020_05_078 crossref_primary_10_1042_BCJ20230096 crossref_primary_10_1111_bjd_18718 crossref_primary_10_1159_000499906 |
| Cites_doi | 10.1002/jcp.1041360118 10.4161/cam.22418 10.1038/nm1504 10.1007/s00109-010-0704-4 10.1016/j.tig.2008.08.010 10.1136/jmg.2005.039685 10.1016/j.molmed.2012.09.008 10.1038/mt.2014.140 10.1371/journal.pone.0087263 10.1038/ng1041 10.1002/cbic.200900779 10.1016/j.jpeds.2007.06.039 10.1016/j.jid.2016.10.038 10.1111/1523-1747.ep12540422 10.1016/S0140-6736(17)31611-2 10.1093/nar/gku608 10.1017/S1355838200000716 10.1172/JCI7866 10.1111/1523-1747.ep12259692 10.1038/nature24487 10.1038/sj.jid.5701197 10.1002/ana.1023 10.1002/jnr.22409 10.1038/nature05756 10.1111/1523-1747.ep12265460 10.1038/nm1197-1280 10.1038/mt.2009.144 10.1111/pde.12157 10.1080/15476286.2016.1219832 10.1136/jmg.2011.089615 10.1073/pnas.0711795105 10.2302/kjm.2014-0013-RE 10.1038/labinvest.3700164 10.1371/journal.pbio.1001593 10.1164/rccm.201001-0137OC 10.1172/JCI92707 10.1371/journal.pgen.1002608 10.1007/s00439-004-1210-y 10.1073/pnas.1312088110 10.1111/1523-1747.ep12491525 10.1016/j.jid.2017.05.011 10.1016/S2213-2600(14)70100-6 10.1038/sj.jp.7211694 10.1016/j.jid.2016.06.609 10.1146/annurev-med-120611-144851 10.1038/sj.clpt.6100012 10.1073/pnas.091484998 10.1074/jbc.M108779200 10.1074/jbc.270.40.23496 10.1111/1523-1747.ep12616168 10.1111/1523-1747.ep12462409 |
| ContentType | Journal Article |
| Copyright | Volumes 1–89 and 106–115, copyright as a collective work only; author(s) retains copyright to individual articles Copyright National Academy of Sciences Jul 10, 2018 2018 |
| Copyright_xml | – notice: Volumes 1–89 and 106–115, copyright as a collective work only; author(s) retains copyright to individual articles – notice: Copyright National Academy of Sciences Jul 10, 2018 – notice: 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 5PM |
| DOI | 10.1073/pnas.1803154115 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts Ecology Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Entomology Abstracts Genetics Abstracts Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | Virology and AIDS Abstracts MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 1091-6490 |
| EndPage | E6545 |
| ExternalDocumentID | PMC6048497 29946029 10_1073_pnas_1803154115 26510935 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -DZ -~X .55 0R~ 123 29P 2AX 2FS 2WC 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADQXQ ADULT AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM BKOMP CS3 D0L DCCCD DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 N9A N~3 O9- OK1 PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR W8F WH7 WOQ WOW X7M XSW Y6R YBH YKV YSK ZCA ~02 ~KM AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QG 7QL 7QP 7QR 7SN 7SS 7T5 7TK 7TM 7TO 7U9 8FD C1K FR3 H94 M7N P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c402t-981eb7160e184aec6bd1911eee9a339b15f858b83cdd6aec69ec94de042fe9fc3 |
| ISSN | 0027-8424 1091-6490 |
| IngestDate | Thu Aug 21 18:04:44 EDT 2025 Fri Sep 05 07:26:48 EDT 2025 Mon Jun 30 08:41:54 EDT 2025 Thu Apr 03 07:03:41 EDT 2025 Tue Jul 01 03:19:50 EDT 2025 Thu Apr 24 23:08:24 EDT 2025 Fri May 30 11:18:43 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 28 |
| Keywords | gentamicin epidermolysis bullosa readthrough |
| Language | English |
| License | Published under the PNAS license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c402t-981eb7160e184aec6bd1911eee9a339b15f858b83cdd6aec69ec94de042fe9fc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Author contributions: J.C. and M.C. designed research; V.L., J.C., Y.H., M. Hirsch, M. Hao, and M.C. performed research; V.A., M.D.L., L.D.R., and J.W.B. contributed new reagents/analytic tools; J.C., Y.H., M. Hirsch, M. Hao, and M.C. analyzed data; and V.L., J.C., D.T.W., and M.C. wrote the paper. 1V.L. and J.C. contributed equally to this work. Edited by James E. Cleaver, University of California, San Francisco, CA, and approved June 4, 2018 (received for review February 21, 2018) |
| PMID | 29946029 |
| PQID | 2100880503 |
| PQPubID | 42026 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6048497 proquest_miscellaneous_2060869088 proquest_journals_2100880503 pubmed_primary_29946029 crossref_primary_10_1073_pnas_1803154115 crossref_citationtrail_10_1073_pnas_1803154115 jstor_primary_26510935 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-07-10 |
| PublicationDateYYYYMMDD | 2018-07-10 |
| PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington |
| PublicationSeriesTitle | PNAS Plus |
| PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
| PublicationTitleAlternate | Proc Natl Acad Sci U S A |
| PublicationYear | 2018 |
| Publisher | National Academy of Sciences |
| Publisher_xml | – name: National Academy of Sciences |
| References | e_1_3_3_50_2 Scudiero DA (e_1_3_3_51_2) 1988; 48 e_1_3_3_16_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_33_2 e_1_3_3_54_2 e_1_3_3_10_2 e_1_3_3_52_2 e_1_3_3_40_2 e_1_3_3_5_2 e_1_3_3_7_2 Chen JK (e_1_3_3_47_2) 2017; 22 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_23_2 e_1_3_3_48_2 e_1_3_3_25_2 e_1_3_3_1_2 Rossi A (e_1_3_3_31_2) 2015; 96 e_1_3_3_44_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 e_1_3_3_17_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_32_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_53_2 e_1_3_3_6_2 e_1_3_3_8_2 e_1_3_3_28_2 e_1_3_3_49_2 e_1_3_3_24_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 Popescu AC (e_1_3_3_46_2) 2010; 88 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 |
| References_xml | – ident: e_1_3_3_53_2 doi: 10.1002/jcp.1041360118 – ident: e_1_3_3_2_2 doi: 10.4161/cam.22418 – ident: e_1_3_3_8_2 doi: 10.1038/nm1504 – ident: e_1_3_3_37_2 doi: 10.1007/s00109-010-0704-4 – ident: e_1_3_3_18_2 doi: 10.1016/j.tig.2008.08.010 – ident: e_1_3_3_12_2 doi: 10.1136/jmg.2005.039685 – ident: e_1_3_3_17_2 doi: 10.1016/j.molmed.2012.09.008 – ident: e_1_3_3_26_2 doi: 10.1038/mt.2014.140 – ident: e_1_3_3_52_2 doi: 10.1371/journal.pone.0087263 – ident: e_1_3_3_30_2 doi: 10.1038/ng1041 – ident: e_1_3_3_38_2 doi: 10.1002/cbic.200900779 – ident: e_1_3_3_6_2 doi: 10.1016/j.jpeds.2007.06.039 – volume: 48 start-page: 4827 year: 1988 ident: e_1_3_3_51_2 article-title: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines publication-title: Cancer Res – ident: e_1_3_3_22_2 doi: 10.1016/j.jid.2016.10.038 – ident: e_1_3_3_48_2 doi: 10.1111/1523-1747.ep12540422 – ident: e_1_3_3_42_2 doi: 10.1016/S0140-6736(17)31611-2 – ident: e_1_3_3_44_2 doi: 10.1093/nar/gku608 – ident: e_1_3_3_45_2 doi: 10.1017/S1355838200000716 – ident: e_1_3_3_13_2 doi: 10.1172/JCI7866 – ident: e_1_3_3_54_2 doi: 10.1111/1523-1747.ep12259692 – ident: e_1_3_3_10_2 doi: 10.1038/nature24487 – ident: e_1_3_3_7_2 doi: 10.1038/sj.jid.5701197 – ident: e_1_3_3_16_2 doi: 10.1002/ana.1023 – volume: 88 start-page: 2316 year: 2010 ident: e_1_3_3_46_2 article-title: Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro publication-title: J Neurosci Res doi: 10.1002/jnr.22409 – ident: e_1_3_3_39_2 doi: 10.1038/nature05756 – ident: e_1_3_3_36_2 doi: 10.1111/1523-1747.ep12265460 – volume: 22 start-page: 9 year: 2017 ident: e_1_3_3_47_2 article-title: Nebulized gentamicin as an alternative to nebulized tobramycin for tracheitis in pediatric patients publication-title: J Pediatr Pharmacol Ther – ident: e_1_3_3_14_2 doi: 10.1038/nm1197-1280 – ident: e_1_3_3_35_2 doi: 10.1038/mt.2009.144 – ident: e_1_3_3_4_2 doi: 10.1111/pde.12157 – ident: e_1_3_3_23_2 doi: 10.1080/15476286.2016.1219832 – ident: e_1_3_3_20_2 doi: 10.1136/jmg.2011.089615 – volume: 96 start-page: e52576 year: 2015 ident: e_1_3_3_31_2 article-title: Generation of a three-dimensional full thickness skin equivalent and automated wounding publication-title: J Vis Exp – ident: e_1_3_3_40_2 doi: 10.1073/pnas.0711795105 – ident: e_1_3_3_11_2 doi: 10.2302/kjm.2014-0013-RE – ident: e_1_3_3_21_2 doi: 10.1038/labinvest.3700164 – ident: e_1_3_3_41_2 doi: 10.1371/journal.pbio.1001593 – ident: e_1_3_3_27_2 doi: 10.1164/rccm.201001-0137OC – ident: e_1_3_3_19_2 doi: 10.1172/JCI92707 – ident: e_1_3_3_34_2 doi: 10.1371/journal.pgen.1002608 – ident: e_1_3_3_3_2 doi: 10.1007/s00439-004-1210-y – ident: e_1_3_3_15_2 doi: 10.1073/pnas.1312088110 – ident: e_1_3_3_29_2 doi: 10.1111/1523-1747.ep12491525 – ident: e_1_3_3_25_2 doi: 10.1016/j.jid.2017.05.011 – ident: e_1_3_3_43_2 doi: 10.1016/S2213-2600(14)70100-6 – ident: e_1_3_3_5_2 doi: 10.1038/sj.jp.7211694 – ident: e_1_3_3_1_2 doi: 10.1016/j.jid.2016.06.609 – ident: e_1_3_3_24_2 doi: 10.1146/annurev-med-120611-144851 – ident: e_1_3_3_33_2 doi: 10.1038/sj.clpt.6100012 – ident: e_1_3_3_9_2 doi: 10.1073/pnas.091484998 – ident: e_1_3_3_50_2 doi: 10.1074/jbc.M108779200 – ident: e_1_3_3_28_2 doi: 10.1074/jbc.270.40.23496 – ident: e_1_3_3_32_2 doi: 10.1111/1523-1747.ep12616168 – ident: e_1_3_3_49_2 doi: 10.1111/1523-1747.ep12462409 |
| SSID | ssj0009580 |
| Score | 2.4897387 |
| Snippet | Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable, devastating, and mostly fatal inherited skin disease for which there is only supportive care.... Premature termination codons (PTCs) generated by nonsense mutations produce abnormal, short, or diminished proteins. Eighty-three percent of patients with... |
| SourceID | pubmedcentral proquest pubmed crossref jstor |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | E6536 |
| SubjectTerms | Anchoring Biological Sciences Cell Adhesion Molecules - genetics Cell Adhesion Molecules - metabolism Cell lines Cell morphology Codon, Nonsense Codons Cytology Epidermolysis bullosa Epidermolysis Bullosa, Junctional - genetics Epidermolysis Bullosa, Junctional - metabolism Epidermolysis Bullosa, Junctional - pathology Expression vectors Filaments Genotype & phenotype Gentamicin Gentamicins - pharmacology HEK293 Cells Humans Integrin alpha6beta4 - genetics Integrin alpha6beta4 - metabolism Junctional epidermolysis bullosa Kalinin Keratinocytes Keratinocytes - metabolism Keratinocytes - pathology Laminin Morphology Mutagenesis - drug effects Mutation Nonsense mutation Phenotypes PNAS Plus Proteins Restoration Skin diseases Three dimensional models |
| Title | Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa |
| URI | https://www.jstor.org/stable/26510935 https://www.ncbi.nlm.nih.gov/pubmed/29946029 https://www.proquest.com/docview/2100880503 https://www.proquest.com/docview/2060869088 https://pubmed.ncbi.nlm.nih.gov/PMC6048497 |
| Volume | 115 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbKuHBBDBgUBjISh6EoJYkTxz4W1K2aurJDi3qL7MQZQ2s7Nc2FA38bfxrPsfOjoyBAqqIqdlwr7-t79vN730PobUCyQGaUulkkiBv6eehKwYgLylKIlHOwWdqhfzGl43l4vogWvd6PTtRSuZWD9NvevJL_kSrcA7nqLNl_kGwzKNyA7yBfuIKE4fpXMj7Tgd9LfTbuwNa61MFVk-HFB-KsdIw0fJxlaaMJYW2Y1TV5qpDyqqIMPKANm_UHAjh0uQiHkEC7Qb62LUrXkd0s14a_RMK2dV2I7rr2srGDRR11MK3djMM2acVqksJxnctpWwJ5oikibir991lk18vmYGR9Zfyz522wwHhdVmYDfuq2NruV63xTmKpWNhFAdP0ZPtOOUhvZ2qED3zu5riIPwLiGJv16oIzuhqWPS0NTfbRR7iZZ1KLY5qEbXT2ikeFe-cWKgNrTpY9Xohj4TJfBCOthdvi6p5-S0_lkksxGi9k9dD-I4ypQ4Gzhd2ifmUmCstOtyaVi8v7O8DvrIhMau2_Tczd2t7MYmj1CD-0uBg8NJA9RT60eo8P6BeITS2b-7gn63mIUW4ziCqO4xiiuMYo7GMWAUVxjFLcYxRajGDAK4-EWo3gHo9hi9Cman45mH8eurfnhpqEXbF3OfCXhPXrKZ6FQKZWZD_ZYKcUFIVz6Uc4iJhlJs4zqdq5SHmYKbE-ueJ6SI3QA81fPEeapzGXuZURXcOA0lBKwkVJBg9TPuCR9NKjfeJJaQnxdl-UmqQIzYpJoESWtiPropHng1nDB_L7rUSXCpl9AI03cBg3HtUwTq0mKJNAMW0wzM_XRm6YZ9Lw-vBMrtS6hj0c9XT2OsT56ZiDQDg46lXoB76N4BxxNB80hv9uyuv5ScclTsOAhj1_8eVov0YP2r3qMDrabUr2CxfhWvq7w_hMd5ecJ |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gentamicin+induces+LAMB3+nonsense+mutation+readthrough+and+restores+functional+laminin+332+in+junctional+epidermolysis+bullosa&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Lincoln%2C+Vadim&rft.au=Cogan%2C+Jon&rft.au=Hou%2C+Yingping&rft.au=Hirsch%2C+Michaela&rft.date=2018-07-10&rft.pub=National+Academy+of+Sciences&rft.issn=0027-8424&rft.eissn=1091-6490&rft.volume=115&rft.issue=28&rft.spage=E6536&rft_id=info:doi/10.1073%2Fpnas.1803154115&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8424&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8424&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8424&client=summon |